← Leaderboards
Anthony Cooper
Javelin Oncology, Inc.
$622,843
Attributed
$622,843
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $328.9K · FY2019–22$500K$375K$250K$125K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$622,843 · 2
By mechanism
R43$622,843 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoPre-ClinicalEngineeringIn VitroNeoplastic CellOncologyChimeric Antigen ReceptorConventional TherapyBindingInfiltrationLeadMalignant NeoplasmsNovel TherapeuticsCancer CellAmericanCellsBaseChimeric Antigen Receptor T CellsCar T Cell TherapyCause Of DeathExperimental StudyGenerationsAntigensPrevalence